HK-LISTED METIS TECHBIO, ELI LILLY STRIKE DRUG-DELIVERY DEAL WORTH UP TO $1.1 BILLION
NEWS Desk Global
4 hours ago
1 min read
Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.
The Chinese biotech will use its proprietary AI-driven drug-delivery platform to develop next-generation technologies aimed at improving how LNP-based drugs reach target tissues.
Comments